5071The monocentric, double-blind, placebo-controlled research of sildenafil impact in pediatric patients with secondary pulmonary hypertension

Purpose: Pulmonary hypertension (PH) caused by congenital cardiac disease continues to be one of the most problematic pediatric diseases to cure. Moreover, PH ultimately faces to RV remodeling and its dysfunction. Sildenafil takes a part of selective inhibitors of phosphodiesterase type 5 class, is famous as an efficient pulmonary vasodilator with insignificant side effects. We have investigated the effectiveness of the aforementioned drug in children with advanced secondary PH CCD with shunts simple (18 ps), mixed (28 ps) and complex (27 ps). Methods: In this study, we performed a monocentric, double-blind, placebo-controlled comparison. 69 children with advanced PAH (39 with repaired congenital SP shunts and persistent PH, 21 with the palliative procedure and 9 inoperable patients) were randomly selected to placebo or sildenafil treatment. The study protocol was accepted by the competent ethical review committee. The patient information and informed consent were provided by all the parents of each child.